Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options
EMD Smith, H Lythgoe, A Midgley, MW Beresford… - Clinical …, 2019 - Elsevier
Juvenile-onset systemic lupus erythematosus (jSLE) accounts for up to 20% of all SLE
patients. Key differences between juvenile-and adult-onset (aSLE) disease include higher …
patients. Key differences between juvenile-and adult-onset (aSLE) disease include higher …
Lupus nephritis
Childhood-onset systemic lupus erythematosus (cSLE) is a subset of SLE with onset prior to
16–18 years of age. Around 15% of patients with SLE present in childhood; patients with …
16–18 years of age. Around 15% of patients with SLE present in childhood; patients with …
Association of rituximab use with adverse events in children, adolescents, and young adults
CL McAtee, J Lubega, K Underbrink, K Curry… - JAMA network …, 2021 - jamanetwork.com
Importance Rituximab is among the most frequently used immunotherapies in pediatrics.
Few studies have reported long-term adverse events associated with its use for children …
Few studies have reported long-term adverse events associated with its use for children …
Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an …
Objectives Application of 'treat-to-target'(T2T) in childhood-onset systemic lupus
erythematosus (cSLE) may improve care and health outcomes. This initiative aimed to …
erythematosus (cSLE) may improve care and health outcomes. This initiative aimed to …
Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature
CB Crayne, E Eloseily, ML Mannion, SP Azerf… - Pediatric …, 2018 - Springer
Abstract Background Henoch-Schonlein purpura (HSP) is a small vessel vasculitis that is
characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and …
characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and …
Belimumab for the treatment of pediatric patients with lupus nephritis
W Stohl, A Kwok - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
Introduction The FDA approved the anti-BAFF monoclonal antibody, belimumab, in 2011 for
adult systemic lupus erythematosus (SLE), in 2019 for pediatric SLE, in 2020 for adult lupus …
adult systemic lupus erythematosus (SLE), in 2019 for pediatric SLE, in 2020 for adult lupus …
Advances in the care of children with lupus nephritis
The care of children with lupus nephritis (LN) has changed dramatically over the past 50 y.
The majority of patients with childhood-onset systemic lupus erythematosus (cSLE) develop …
The majority of patients with childhood-onset systemic lupus erythematosus (cSLE) develop …
Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review
Objectives To evaluate the efficacy and safety of rituximab for treating pediatric systemic
lupus erythematosus (pSLE). Study design We performed a systematic review to evaluate …
lupus erythematosus (pSLE). Study design We performed a systematic review to evaluate …
Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey
L Bartolini, E Muscal - Journal of neurology, 2017 - Springer
The objective of the study was to identify differences in treatment strategies for anti-NMDA
receptor encephalitis based on specialty of treating physicians, geographic location, and …
receptor encephalitis based on specialty of treating physicians, geographic location, and …
Current views on lupus in children
EMD Smith, H Lythgoe, CM Hedrich - Current Opinion in …, 2023 - journals.lww.com
Recent studies have significantly improved our understanding of jSLE pathogenesis,
highlighting important differences between jSLE and adult SLE, and providing the basis of …
highlighting important differences between jSLE and adult SLE, and providing the basis of …